Dublin, May 22, 2018 (GLOBE NEWSWIRE) -- The "Global Antibody Partnering Terms and Agreements 2010-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering. The Global Antibody Partnering Terms and Agreements 2010 to 2018 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. Report scope Global Antibody Partnering Terms and Agreements 2010 to 2018 includes:
- Trends in Antibody dealmaking in the biopharma industry since 2010
- Analysis of Antibody deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Antibody deals
- Access to over 1,200 Antibody online deal records
- The leading Antibody deals by value since 2010
- Most active Antibody dealmakers since 2010
- The leading Antibody partnering resources
In Global Antibody Partnering Terms and Agreements 2010 to 2018, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:
- Antibodies
- Antibody-drug conjugates
- Monoclonal antibodies
- Murine mAb
- Chimeric mAb
- Humanized mAb
- Human aAb
- Polyclonal Antibodies
Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in antibody dealmaking 2.1. Introduction 2.2. Antibody partnering over the years 2.3. Most active antibody dealmakers 2.4. Antibody partnering by deal type 2.5. Antibody partnering by therapy area 2.6. Deal terms for antibody partnering 2.6.1 Antibody partnering headline values 2.6.2 Antibody deal upfront payments 2.6.3 Antibody deal milestone payments 2.6.4 Antibody royalty rates Chapter 3 - Leading antibody deals 3.1. Introduction 3.2. Top antibody deals by value Chapter 4 - Most active antibody dealmakers 4.1. Introduction 4.2. Most active antibody dealmakers 4.3. Most active antibody partnering company profiles Chapter 5 - Antibody contracts dealmaking directory 5.1. Introduction 5.2. Antibody contracts dealmaking directory Chapter 6 - Antibody dealmaking by technology type Chapter 7 - Partnering resource center 7.1. Online partnering 7.2. Partnering events 7.3. Further reading on dealmaking Appendices Appendix 1 - Antibody deals by company A-Z Appendix 2 - Antibody deals by stage of development Discovery Preclinical Phase I Phase II Phase III Regulatory Marketed Formulation Appendix 3 - Antibody deals by deal type Asset purchase Assignment Bigpharma outlicensing Co-development Collaborative R&D Co-market Co-promotion CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Material transfer Option Promotion Research Settlement Spin out Sub-license Supply Technology transfer Termination Appendix 4 - Antibody deals by therapy area Cardiovascular Central Nervous System Dental Dermatology Gastrointestinal Hematology Hospital care Immunology Infectives Metabolic Musculoskeletal Obstetrics Oncology Ophthalmics Orphan disease Pediatrics Psychiatry Respiratory Appendix 5 - Deal type definitions For more information about this report visit https://www.researchandmarkets.com/research/q...ibody?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Oncology Drugs
